A surge in demand for GLP-1 receptor agonist drugs such as Ozempic has transformed them from treatments primarily for type 2 diabetes into popular weight-loss medications, fueling shortages, cultural trends, and now thousands of lawsuits alleging serious side effects.
Novo Nordisk’s Ozempic (semaglutide) and similar drugs from Eli Lilly have seen prescriptions explode, with off-label use for weight loss driving much of the growth. As of recent reports, over 4,000 lawsuits have been filed against the manufacturers, consolidated in federal multidistrict litigation, with claims centered on gastrointestinal injuries and vision loss.
From Diabetes Drug to Weight-Loss Phenomenon
Ozempic received FDA approval in 2017 for type 2 diabetes. It mimics the GLP-1 hormone to regulate blood sugar and slow digestion. Clinical trials later showed significant weight-loss benefits, leading to approvals for obesity treatments like Wegovy (semaglutide) in 2021 and Zepbound (tirzepatide) in 2023.
Prescriptions for GLP-1 drugs more than tripled since 2020, reaching about 9 million by late 2023. Usage doubled between 2024 and 2025 in some analyses. Approximately 12% of U.S. adults (about 1 in 8) have used a GLP-1 drug, with 11-12% currently using one as of 2025-2026 surveys.
By 2023, almost 50% of GLP-1 prescriptions were for purposes other than diabetes.
Telehealth services contributed to nearly 50% of this increase, facilitating swift access for weight loss related to cosmetic reasons, per Drugwatch.
Women use these drugs at higher rates than men (15% vs. 9% currently). Peak usage occurs among adults aged 50-64, where about 22% are currently taking them, with women in this group showing the highest rates (around 1 in 5 have tried them). Use is lower among those 65 and older, partly due to Medicare coverage limitations.
Shortages and Cultural Impact
The drugs’ popularity created widespread shortages, hitting diabetes patients hardest as off-label weight-loss demand surged via social media and telehealth. By 2023, new prescriptions hit record highs, with semaglutide dominating. The FDA eventually declared shortages resolved in late 2024 and early 2025.
Pros include effective blood sugar control, average weight loss of 15-20% or more in trials, and cardiovascular benefits such as reduced risk of major events. Some studies note potential additional effects like lower risks for certain conditions, though long-term data continues to evolve.
Common side effects are gastrointestinal: nausea (reported by about half of users), diarrhea (about one-third), vomiting, constipation, and acid reflux. Many patients stop due to these or cost.
Lawsuits and Alleged Serious Risks
As of early 2026, over 4,400 lawsuits were filed in federal and state courts, with more than 3,800 pending in the main MDL for GI injuries and a separate track for vision loss. Plaintiffs allege manufacturers Novo Nordisk and Eli Lilly failed to adequately warn about risks.
Some reports reference potential damages in the billions, though no global settlements have been reached; bellwether trials are expected in late 2026 or 2027. Drugmakers maintain the drugs are safe when used as prescribed and deny liability.
Claims of a roughly $2 billion lawsuit involving about 1,800 users alleging vision loss and links to aggressive thyroid cancer. Court data shows thousands of cases overall focused primarily on GI injuries (e.g., gastroparesis in ~75% of sampled claims) and vision loss (at least 110 plaintiffs), with thyroid concerns tied to a boxed warning from rodent studies.
Human studies have not shown a clear increased risk for common thyroid cancers, and thyroid claims are not the primary track in the active MDLs.
More serious, reported issues in lawsuits and adverse event data include gastroparesis (stomach paralysis), intestinal blockages, gallbladder problems, pancreatitis, and NAION (non-arteritic anterior ischemic optic neuropathy), a form of sudden vision loss.
“Ozempic Face” and Aesthetic Changes
Rapid weight loss has also produced the phenomenon known as “Ozempic face,” characterized by sagging skin, hollowed cheeks, sunken eyes, and a gaunt appearance due to facial fat and some muscle loss. Studies quantify midfacial volume loss at around 7-11% with typical weight reduction on these drugs. Plastic surgeons report increased demand for corrective procedures.
Broader Implications
This shift has altered perceptions of healthy weight management. What began as a medical intervention for diabetes has become a cultural tool for cosmetic weight loss, raising questions about supply allocation, long-term adherence (many regain weight after stopping), and societal standards for body image.
Compounded versions during shortages added further safety concerns, prompting manufacturer lawsuits against some sellers.
Provided by Dallas Express
